US Patent

US8871761 — NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders

Composition of Matter · Assigned to Euroscreen SA · Expires 2031-04-04 · 5y remaining

Vulnerability score 18/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects novel compounds of formula I and their use as therapeutic compounds, specifically targeting NK-3 receptors.

USPTO Abstract

The present invention is directed to novel compounds of formula I and their use as therapeutic compounds.

Drugs covered by this patent

Patent Metadata

Patent number
US8871761
Jurisdiction
US
Classification
Composition of Matter
Expires
2031-04-04
Drug substance claim
Yes
Drug product claim
No
Assignee
Euroscreen SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.